William S. Marshall - Boulder CO Kevin Lee Stark - Thousand Oaks CA
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C12P 2106
US Classification:
435 691
Abstract:
The present invention concerns therapeutic agents that antagonize the activity of glucagon. In accordance with the present invention, the compounds of the invention comprise: a. a glucagon antagonist domain, preferably the amino acid sequence of SEQ ID NO: 7, or sequences derived therefrom by phage display, RNA-peptide screening, or the other techniques; and b. a vehicle, such as a polymer (e. g. , PEG or dextran) or an Fc domain, which is preferred; wherein the vehicle is covalently attached to the glucagon antagonist domain. The vehicle and the glucagon antagonist domain may be linked through the N- or C-terminus of the glucagon antagonist domain. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.
Stacy Koester, Kelly Deiter, Jeremy Carlson, Deena Cunningham, Konni Giesen, Liz Pritchard, Teresa Beckman, Eric Hoefert, Brian King, Nate Hoefert, Matthew Wilhelm
Alan Alford, Joe Fahrenbacher, Joan Birchfield, Jennifer Wienhoff, Jenny Semones, Brad Boll, David Stark, Meredith Amburn, Maureen Dolan, Billy Madison, Holly Powell, Debbie Earnest